Thibault Boutherin
Stock Analyst at Morgan Stanley
(3.47)
# 2,329
Out of 4,609 analysts
161
Total ratings
61.8%
Success rate
6.3%
Average return
Main Sectors:
Stocks Rated by Thibault Boutherin
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SWX: NOVN Novartis AG | Maintained: Buy | CHF 135.00 | CHF 125.18 | +7.84% | 13 | Jun 25, 2026 | |
| LON: 0QIU Novo Nordisk A/S | Maintained: Hold | kr 270.00 → kr 250.00 | kr 295.26 | -15.33% | 6 | May 7, 2026 | |
| SWX: GALD Galderma Group AG | Maintained: Hold | CHF 155.00 → CHF 160.00 | CHF 178.25 | -10.24% | 9 | Apr 27, 2026 | |
| NVS Novartis AG | Maintained: Buy | $143 → $170 | $154.21 | +10.24% | 3 | Mar 26, 2026 | |
| ETR: BAYN Bayer Aktiengesellschaft | Maintained: Buy | €40.00 → €53.00 | €49.40 | +7.29% | 5 | Mar 11, 2026 | |
| BME: GRF Grifols, S.A. | Downgraded: Hold | €12.00 → €11.00 | €10.11 | +8.86% | 7 | Mar 10, 2026 | |
| NVO Novo Nordisk | Upgraded: Hold | $42 → $40 | $45.97 | -12.99% | 5 | Mar 3, 2026 | |
| INDV Indivior Pharmaceuticals | Maintained: Buy | $28 → $36 | $38.67 | -6.90% | 11 | Dec 3, 2025 | |
| ETR: MRK Merck KGaA | Maintained: Hold | €130.00 → €135.00 | €145.15 | -6.99% | 5 | Dec 3, 2025 | |
| SWX: LONN Lonza Group AG | Maintained: Buy | CHF 650.00 | CHF 566.60 | +14.72% | 10 | Dec 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $14 → $10 | $3.80 | +163.16% | 4 | Dec 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | CHF 38.00 → CHF 50.00 | CHF 69.18 | -27.72% | 4 | Dec 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | €300.00 | €229.50 | n/a | 3 | Apr 22, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | €250.00 | €174.30 | n/a | 3 | Apr 22, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | €715.00 | €758.30 | n/a | 1 | Mar 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | 2,100p → 2,400p | 1,699p | n/a | 15 | Feb 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $14 | $1.95 | n/a | 1 | Jul 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | €12.00 | €3.43 | n/a | 1 | Jul 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | 912p | 1,291p | n/a | 1 | Jul 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | €120.00 | €161.90 | n/a | 18 | May 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $37 → $40 | $85.14 | n/a | 2 | May 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Sell | CHF 4.00 → CHF 1.00 | CHF 6.01 | n/a | 11 | Apr 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgraded: Hold | €0.87 → €105.00 | €228.92 | n/a | 12 | Mar 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $16 | $7.83 | n/a | 4 | Dec 29, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | €11.50 → €11.00 | €10.98 | n/a | 5 | Nov 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $10 | $34.81 | n/a | 2 | Oct 4, 2023 |
Novartis AG
Jun 25, 2026
Maintained: Buy
Price Target: CHF 135.00
Current: CHF 125.18
Upside: +7.84%
Novo Nordisk A/S
May 7, 2026
Maintained: Hold
Price Target: kr 270.00 → kr 250.00
Current: kr 295.26
Upside: -15.33%
Galderma Group AG
Apr 27, 2026
Maintained: Hold
Price Target: CHF 155.00 → CHF 160.00
Current: CHF 178.25
Upside: -10.24%
Novartis AG
Mar 26, 2026
Maintained: Buy
Price Target: $143 → $170
Current: $154.21
Upside: +10.24%
Bayer Aktiengesellschaft
Mar 11, 2026
Maintained: Buy
Price Target: €40.00 → €53.00
Current: €49.40
Upside: +7.29%
Grifols, S.A.
Mar 10, 2026
Downgraded: Hold
Price Target: €12.00 → €11.00
Current: €10.11
Upside: +8.86%
Novo Nordisk
Mar 3, 2026
Upgraded: Hold
Price Target: $42 → $40
Current: $45.97
Upside: -12.99%
Indivior Pharmaceuticals
Dec 3, 2025
Maintained: Buy
Price Target: $28 → $36
Current: $38.67
Upside: -6.90%
Merck KGaA
Dec 3, 2025
Maintained: Hold
Price Target: €130.00 → €135.00
Current: €145.15
Upside: -6.99%
Lonza Group AG
Dec 3, 2025
Maintained: Buy
Price Target: CHF 650.00
Current: CHF 566.60
Upside: +14.72%
Dec 3, 2025
Maintained: Buy
Price Target: $14 → $10
Current: $3.80
Upside: +163.16%
Dec 3, 2025
Maintained: Hold
Price Target: CHF 38.00 → CHF 50.00
Current: CHF 69.18
Upside: -27.72%
Apr 22, 2025
Maintained: Buy
Price Target: €300.00
Current: €229.50
Upside: n/a
Apr 22, 2025
Maintained: Buy
Price Target: €250.00
Current: €174.30
Upside: n/a
Mar 5, 2025
Maintained: Buy
Price Target: €715.00
Current: €758.30
Upside: n/a
Feb 12, 2025
Maintained: Hold
Price Target: 2,100p → 2,400p
Current: 1,699p
Upside: n/a
Jul 29, 2024
Downgraded: Hold
Price Target: $14
Current: $1.95
Upside: n/a
Jul 29, 2024
Downgraded: Hold
Price Target: €12.00
Current: €3.43
Upside: n/a
Jul 15, 2024
Maintained: Buy
Price Target: 912p
Current: 1,291p
Upside: n/a
May 15, 2024
Maintained: Hold
Price Target: €120.00
Current: €161.90
Upside: n/a
May 8, 2024
Maintained: Hold
Price Target: $37 → $40
Current: $85.14
Upside: n/a
Apr 3, 2024
Maintained: Sell
Price Target: CHF 4.00 → CHF 1.00
Current: CHF 6.01
Upside: n/a
Mar 25, 2024
Upgraded: Hold
Price Target: €0.87 → €105.00
Current: €228.92
Upside: n/a
Dec 29, 2023
Maintained: Hold
Price Target: $16
Current: $7.83
Upside: n/a
Nov 13, 2023
Maintained: Hold
Price Target: €11.50 → €11.00
Current: €10.98
Upside: n/a
Oct 4, 2023
Maintained: Hold
Price Target: $10
Current: $34.81
Upside: n/a